| Brittany E Goodrich-braun, | |
|
3925 N Gateway Dr, Appleton, WI 54913-7863 | |
| (920) 830-6877 | |
| Not Available |
| Full Name | Brittany E Goodrich-braun |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 8 Years |
| Location | 3925 N Gateway Dr, Appleton, Wisconsin |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013362631 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 71265-20 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Thedacare Regional Med Ctr - Neenah | Neenah, WI | Hospital |
| Thedacare Regional Medical Center - Appleton Inc | Appleton, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Partnership Community Health Center Inc | 2062452600 | 7 |
News Archive
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced today that the U.S. Food and Drug Administration has determined that a new drug application (NDA) for Otsuka's investigational once-monthly aripiprazole depot formulation for the indication of maintenance treatment of schizophrenia in adults is sufficiently complete to permit a substantive review.
Scientists have shown that a brand new type of cancer pill that exploits the emerging field of epigenetics is safe for human use, according to a Phase I trial reported today in Clinical Cancer Research.
UCLA scientists have discovered that an overlooked region in brain cells houses a motherlode of mutated genes previously tied to autism. Recently published in Neuron, the finding could provide fresh drug targets and lead to new therapies for the disorder, which affects one in 68 children in the United States.
Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that patent applications related to its rapid prototyping system for the manufacture of microfluidic chips, or Lab-on-a-Chip (LOC) devices, have been filed.
› Verified 2 days ago
| Entity Name | Thedacare Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376656959 PECOS PAC ID: 1759294887 Enrollment ID: O20031106000088 |
News Archive
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced today that the U.S. Food and Drug Administration has determined that a new drug application (NDA) for Otsuka's investigational once-monthly aripiprazole depot formulation for the indication of maintenance treatment of schizophrenia in adults is sufficiently complete to permit a substantive review.
Scientists have shown that a brand new type of cancer pill that exploits the emerging field of epigenetics is safe for human use, according to a Phase I trial reported today in Clinical Cancer Research.
UCLA scientists have discovered that an overlooked region in brain cells houses a motherlode of mutated genes previously tied to autism. Recently published in Neuron, the finding could provide fresh drug targets and lead to new therapies for the disorder, which affects one in 68 children in the United States.
Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that patent applications related to its rapid prototyping system for the manufacture of microfluidic chips, or Lab-on-a-Chip (LOC) devices, have been filed.
› Verified 2 days ago
| Entity Name | Partnership Community Health Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225074008 PECOS PAC ID: 2062452600 Enrollment ID: O20140213001404 |
News Archive
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced today that the U.S. Food and Drug Administration has determined that a new drug application (NDA) for Otsuka's investigational once-monthly aripiprazole depot formulation for the indication of maintenance treatment of schizophrenia in adults is sufficiently complete to permit a substantive review.
Scientists have shown that a brand new type of cancer pill that exploits the emerging field of epigenetics is safe for human use, according to a Phase I trial reported today in Clinical Cancer Research.
UCLA scientists have discovered that an overlooked region in brain cells houses a motherlode of mutated genes previously tied to autism. Recently published in Neuron, the finding could provide fresh drug targets and lead to new therapies for the disorder, which affects one in 68 children in the United States.
Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that patent applications related to its rapid prototyping system for the manufacture of microfluidic chips, or Lab-on-a-Chip (LOC) devices, have been filed.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brittany E Goodrich-braun, 3 Neenah Ctr, Neenah, WI 54956-3070 Ph: (920) 830-5900 | Brittany E Goodrich-braun, 3925 N Gateway Dr, Appleton, WI 54913-7863 Ph: (920) 830-6877 |
News Archive
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced today that the U.S. Food and Drug Administration has determined that a new drug application (NDA) for Otsuka's investigational once-monthly aripiprazole depot formulation for the indication of maintenance treatment of schizophrenia in adults is sufficiently complete to permit a substantive review.
Scientists have shown that a brand new type of cancer pill that exploits the emerging field of epigenetics is safe for human use, according to a Phase I trial reported today in Clinical Cancer Research.
UCLA scientists have discovered that an overlooked region in brain cells houses a motherlode of mutated genes previously tied to autism. Recently published in Neuron, the finding could provide fresh drug targets and lead to new therapies for the disorder, which affects one in 68 children in the United States.
Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that patent applications related to its rapid prototyping system for the manufacture of microfluidic chips, or Lab-on-a-Chip (LOC) devices, have been filed.
› Verified 2 days ago
Michael John Van Abel, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 3916 N Intertech Ct, Appleton, WI 54913 Phone: 920-996-1000 | |
Stephen C Fuller, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3916 N Intertech Ct, Appleton, WI 54913 Phone: 920-996-1000 | |
Samuel James Heiks, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3916 N Intertech Ct, Appleton, WI 54913 Phone: 920-996-1000 Fax: 920-996-1054 | |
Dirk Jon Derksen, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 10 Wagon Wheel Dr, Appleton, WI 54913 Phone: 920-731-6374 | |
Ms. Cynthia Frances Susedik, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3925 N Gateway Dr, Appleton, WI 54913 Phone: 920-830-6877 Fax: 920-993-5037 | |
N Carter Noble, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3329 N Richmond St, Appleton, WI 54911 Phone: 920-380-2715 |